Mr. Handrinos is described as a “superb attorney – exceptionally bright, attentive to details and remarkably hard working” and “a real legal expert in corporate and securities matters” who “has deep technical knowledge and good commercial perspective.”Chambers USA

Peter N. Handrinos

Boston | New York
  • 200 Clarendon Street
  • Boston, MA 02116
  • USA

Peter Handrinos practices corporate and securities law, with an emphasis on mergers and acquisitions, capital markets and venture capital transactions for life sciences and technology companies. Mr. Handrinos advises both public and private companies on a range of matters, including:

  • IPOs
  • Follow-on offerings
  • Strategic investments
  • 144A offerings
  • Cash and stock mergers
  • Tender offers
  • Going-private transactions

He counsels numerous startup companies and venture capital firms in venture capital financings. Mr. Handrinos also regularly represents investment banks in connection with capital markets transactions. A significant portion of his practice involves general corporate work for ongoing clients on matters such as SEC compliance, securities and disclosure issues, and corporate governance matters.

The Legal 500 USA describes Mr. Handrinos as “one of the best life sciences lawyers in Boston.” He has been recognized as a leader in Corporate/M&A by Chambers USA since 2007, where he is also described as a “superb attorney – exceptionally bright, attentive to details and remarkably hard working” and "a real legal expert in corporate and securities matters“ who “has deep technical knowledge and good commercial perspective.” Mr. Handrinos is recognized as a Life Sciences Star in the 2016 LMG Life Sciences Guide. He has also been listed in the 2012 through 2016 editions of Best Lawyers in America as a leader in mergers and acquisitions.

Mr. Handrinos has advised the following clients on their IPOs: 

  • Selecta Biosciences
  • Merus
  • Seres Therapeutics
  • Press Ganey
  • Valeritas
  • T2 Biosystems
  • Radius Health
  • BIND Therapeutics
  • Aratana Therapeutics

Mr. Handrinos has advised the underwriters for the following IPOs: 

  • Ra Pharmaceuticals
  • Kadmon Holdings
  • Intellia Therapeutics
  • Clearside Biomedical
  • American Renal Associates
  • Aclaris Therapeutics
  • Blueprint Medicines Corporation
  • CoLucid Pharmaceuticals
  • Flex Pharma
  • Collegium Pharmaceutical
  • Agile Therapeutics
  • Akebia Therapeutics
  • Auspex Pharmaceuticals
  • Applied Genetic Technologies Corp
  • Trevena
  • Cara Therapeutics
  • Mazor Robotics
  • Tetraphase Pharmaceuticals

In addition, Mr. Handrinos’ representative transactions include representing:

  • Assurex Health in its US$225 million sale to Myriad Genetics 
  • Press Ganey in its US$2.35 billion sale to EQT
  • Babyganics in its sale to SC Johnson & Son Inc.
  • Datto, Inc. in its Series B Preferred Stock Financing 
  • Jefferies and Barclays in follow-on public offerings by Trevena
  • Stifel and Piper in a follow-on public offering by Cara Therapeutics
  • BofA Merrill Lynch and Cowen in a follow-on public offering by Dyax Corp.
  • UBS and Morgan Stanley in a follow-on offering by Akebia Therapeutics
  • Aratana Therapeutics in its:
    • PIPE and follow-on offerings
    • Acquisition of Okapi Sciences BV
    • Acquisition of Vet Therapeutics Inc.
  • Radius Health in its follow-on offerings
  • BIND Therapeutics in its follow-on offerings
  • Morgan Stanley and BAML in a follow-on offering by Sarepta Therapeutics
  • BMO and Stifel in follow-on offerings by Tetraphase Pharmaceuticals
  • Chiasma in its US$595 million collaboration with Roche
  • JP Morgan, Cowen, and Jefferies in a follow-on offering by ARIAD            
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.